NOVANTA INC 8K

Novanta Inc. completed the acquisition of Riverpoint Medical from Arlington Capital Partners, a deal expected to significantly increase Novanta’s medical consumables revenue and be accretive to growth, margins, and earnings starting in 2027.

On July 27, 2026, Novanta Inc. announced that it has completed the acquisition of Riverpoint Medical from Arlington Capital Partners, adding a high-growth, minimally invasive surgical consumables business that is expected to double Novanta’s recurring medical consumables revenue to approximately $300 million and increase its medical end-market exposure to 60% of total revenue. Management projects the deal will be immediately accretive to organic growth, adjusted gross margin, adjusted EBITDA growth and margin, and cash flows, with a high single-digit return on invested capital by year three, meeting the company’s return hurdle rate by year five, and contributing an estimated $0.18 to $0.25 of adjusted EPS in 2027. Riverpoint Medical will be integrated into Novanta’s Medical Solutions operating segment, and the company will provide further detail on the 2026 financial impact during its upcoming second quarter earnings call, while cautioning that these expectations are forward-looking and subject to integration and other execution risks.

Filing Facts

CIK

1076930

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-316947

Alert Tier

8